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Summary. In the anaesthetized rabbit, L-NG-monomethyl-arginine (L-
NMMA) , a specific inhibitor of nitric oxide (NO) formation, was used to 
assess the role of endothelium-derived NO in the regulation of haemodynamics 
and noradrenaline release (RNA). L-NMMA dose-dependently increased mean 
arterial pressure and total peripheral resistance (TPR) , but decreased heart 
rate, cardiac output and RNA. The curvilinear relationship between RNA 
and TPR obtained for L-NMMA was virtually identical with that produced 
by phenylephrine, indicating that L-NMMA-induced decreases in RNA are 
mediated by the baroreflex. Since the maximum RNA inhibition by L-NMMA 
was 69%, the counterregulation against peripheral vasodilatation by 
endothelium-derived NO accounts for 69% of basal RNA. 
Introduction 
Vascular smooth muscle tone is regulated predominantly by two counter-
acting mechanisms: a) vasoconstriction which is dependent mainly on 
sympathetic" tone as reflected by the release of noradrenaline and b) vaso-
dilatation induced by endothelium-derived relaxing factor (ED RF). ED RF 
is considered to be identical with nitric oxide (NO) formed enzymatically 
from L-arginine within the endothelial cells (Palmer et aI., 1988a; Schmidt 
et aI., 1988). The L-arginine analogue L-NG-monomethyl-arginine 
(L-NMMA) has been shown to act as competitive inhibitor of this NO 
formation from L-arginine (Palmer et aI., 1988b; Sakuma et aI., 1988). 
Furthermore, i.v. administration of L-NMMA has been reported to increase 
blood pressure and to decrease heart rate in the anaesthetized rabbit (Rees 
et aI., 1989) and guinea pig (Aisaka et aI., 1989). From these studies the 
question arises, whether a continuous basal release of NO not only leads to 
vasodilatation, but also modulates vascular tone by affecting noradrenaline 
release. Therefore, the present study aimed at examining the role of 
endothelium-derived NO in the regulation of haemodynamics and of 
noradrenaline release. L-NMMA was used to inhibit NO formation and 
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phenylephrine to assess baroreflex-mediated changes III noradrenaline 
release. 
Methods 
Experimental procedure 
Rabbits (Chinchilla bastards; 2.0-2.5kg) of either sex were anaesthetized by i.v. 
injection of SaffanR (1: 3 mixture of alfadolone and alfaxalone) and artificially respired 
with room air as described by Szabo et ai. (1989). The left femoral artery and vein as 
well as the right atrium and carotid artery were cannulated with polyethylene tubing. 
Arterial pressure was recorded from the right carotid artery. Heart rate was obtained 
from the arterial pressure signal by means of a heart rate integrator. Cardiac output 
was determined by the thermodilution technique with a cardiac output computer. 
After vessel cannulation, rabbits were infused via the left femoral vein with 3H_ 
(-)-noradrenaline (70nCikg- l min- l ) to determine the plasma clearance of 3H_ 
noradrenaline (see below). Blood samples for the determination of plasma levels of 
3H-labelled and unlabelled noradrenaline were collected from the left femoral artery 
(in ice-cold tubes) and centrifuged immediately. 
For determination of baseline values, haemodynamic measurements were carried 
out and blood samples were taken 60 min after initiation of the 3H-noradrenaline 
infusion. Thereafter, rabbits were given either L-NMMA to inhibit NO formation 
or infused with phenylephrine to produce uI-adrenoceptor-mediated peripheral 
vasoconstriction. 
In the L-NMMA group, rabbits were given three i.v. bolus injections at lO-min 
intervals to make up cumulative L-NMMA doses of 3, 10 and 30 (n = 7) or 10, 30 and 
100 mg kg- I (n = 9). In three out of these experiments with the final L-NMMA dose of 
30mgkg-I, L-arginine (90mgkg-I) was given i.v. 10min after the last L-NMMA 
injection in order to test whether the L-NMMA effects are susceptible to attenuation 
by L-arginine. At the end of each lO-min interval and 20 min after the L-arginine dose, 
haemodynamic measurements and blood sampling were repeated. L-NMMA was given 
in a cumulative manner, because the effects of single doses of L-NMMA have been 
shown to be fairly long-lasting (cf. Rees et ai. ,1989). 
Phenylephrine was infused i.v. in two or three consecutive lO-min infusion periods 
at rates of 2.5 and 5 (n = 7), or 2.5, 5 and 10 (n = 9), or 5, 10 and 20 (n = 5) 
Ilg kg -I min - I. Haemodynamic measurements were carried out and blood samples 
were taken at the end of each infusion period. 
Control experiments in five vehicle-treated rabbits revealed that, during a 50-min 
observation period, there were no time-dependent changes in any of the parameters 
studied. 
Analytical procedure 
After adsorption onto Ah03 and desorption with 0.1 moll- I HCI04 , plasma 
concentrations of noradrenaline were determined by reversed phase HPLC and 
ekctrochemical detection, with the plasma levels of endogenous noradrenaline being 
corrected for the analytical recovery determined in each assay (Halbriigge et aI., 1988). 
Timed collections of the eluent leaving the HPLC system also allowed quantification of 
3H-noradrenaline by liquid scintillation counting. "Blank" plasma, which was spiked 
with known amounts (10 Ill) of the 3H-noradrenaline-containing infusate, was subjected 
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to HPLC and liquid scintillation counting as well, to determine the 3H-noradrenaline 
infusion rate in each individual experiment (see below). 
Calculations and statistics 
The plasma clearance of 3H-Iabelled noradrenaline was determined from the ratio of 
,,3H-noradrenaline infusion rate/steady-state plasma level of 3H-noradrenaline" and 
expressed in ml kg -1 min -1. Both parameters of the above ratio were obtained from the 
amount of radioactivity co-eluting with unlabelled noradrenaline from the HPLC 
system after Ah03 extraction of };lasma. This procedure circumvented the need to 
determine analytical recoveries of H-noradrenaline. The rate of release into plasma of 
endogenous noradrenaline was obtained from the product of ,,3H-noradrenaline plasma 
clearance x plasma level of endogenous noradrenaline" and expressed in pmol 
kg -1 min -1. Total peripheral resistance was calculated from the ratio of "a-rterio-
venous pressure difference/cardiac output" and expressed in Pa s ml- I . 
Dose-response curves were obtained from a least squares fit based on Hill's 
equation, and regression lines were calculated by the method of least squares. Results 
are given as arithmetic means ± SEM. To test the significance of drug-induced effects, 
the paired or unpaired Student's t-test was used. A P value < 0.05 was taken to 
indicate statistical significance. 
Substances used in this study 
L-NG-Monomethyl-arginine (L-NMMA) was prepared according to the method of 
Corbin and Reporter (1974). The flavin ate salt was converted to the hydrochloride salt 
by stirring with a suspension of Dowex-l (OH- form) and titrating the resulting 
solution of the free base to pH 7.2 with hydrochloric acid_ The identity and purity of 
the compound was confirmed by amino acid analysis. 
SaffanR ampoules (alfadolone: alfaxalone = 1: 3, 12 mg ml- I ; Schweizerisches 
Serum and Impfinstitut, Bern, Switzerland); (-)-phenylephrine HCI, L-arginine HCl, 
(-)-noradrenaline bitartrate (Serva, Heidelberg, FRG); Dowex-1 (Cl- form), flavianic 
acid (Sigma Chemie, Deisenhofen, FRG); 3H-7-(-)-noradrenaline (NET-377, 
14.2Cimmol- I ) (NEN, Dreieich, FRG). The doses of drugs refer to free bases. 
Results 
Haemodynamics 
Pretreatment baseline values of haemodynamic parameters in the L-NMMA 
group of animals are given in the legend to Table 1. There was no statis-
tically significant difference between the L-NMMA and the phenylephrine 
group. in any of the baseline values. 
Both phenylephrine (2.5, 5, 10 and 20 ~gkg-I min-I) and L-NMMA (3, 
10,30 and 100mgkg-l) dose-dependently increased mean arterial pressure 
and total peripheral resistance, but decreased heart rate and cardiac output. 
From the dose-response relationships for L-NMMA, but not from those for 
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Table 1. Dose-response parameters for the effects of L-NMMA on haemodynamics in 
anaesthetized rabbits 
Emax 
ED so (mg kg-I) 
nH 
LlMAP (mm Hg) LlHR (min-I) LlCO (ml min-I) LlTPR (Pa s ml- I) 
19.1 ± 0.6 
11.2 ± 1.1 
0.8 ± 0.1 
-62.3 ± 8.8 
13.4 ± 5.8 
0.8 ± 0.2 
-80.1 ± 8.8 
7.9 ± 2.8 
0.7 ± 0.2 
1227 ± 373 
18.5 ± 19.9 
0.7 ± 0.3 
Results (means ± asymptotic standard error) were calculated by fitting Hill's equation 
to the mean group results obtained lOmin after i.v. bolus injection of cumulative 
L-NMMA doses of 3 (n = 7), 10 (n = 16),30 (n = 16) and 100 (n = 9)mgkg-l. Mean 
group baseline values (±SEM, n = 16 each) for the above parameters were as follows: 
mean arterial pressure (MAP) 64 ± 2mmHg, heart rate (HR) 285 ± 6min- I, cardiac 
output (CO) 336 ± 12mlmin- I, and total peripheral resistance (TPR) 1457 ± 56 Pa s 
ml- 1 
phenylephrine, dose-response parameters for the haemodynamic effects 
were obtained. The results are summarized in Table 1. 
L-arginine (90 mg kg -1), which has been reported to have no direct 
effect on either mean arterial pressure or heart rate (Rees et al., 1989), 
attenuated the effects of L-NMMA (30mgkg-1) on heart rate and cardiac 
output by about 70% and abolished the L-NMMA effects on blood pressure 
and total peripheral resistance. 
Release of noradrenaline 
In the L-NMMA group of animals (n = 16), the baseline values of plasma 
noradrenaline concentration and plasma clearance were 1.88 ± 0.17nmoll-1 
and 79.9 ± 2.0 ml kg-1 min-I, respectively. The corresponding values 
obtained in the phenylephrine group (n = 21) amounted to 2.09 ± 
0.16 nmoll-1 and 84.7 ± 2.4 ml kg -1 min -1, respectively. Baseline values for 
the rates of noradrenaline release into plasma are given in the legend to 
Fig. 1. There was no statistically significant difference in any of these 
baseline values between both groups of animals. 
Both phenylephrine and L-NMMA not only dose-dependently decreased 
the plasma noradrenaline concentration, but also decreased the nor-
adrenaline plasma clearance. Moreover, the results obtained with both 
drugs fell onto a single regression line relating noradrenaline plasma clear-
ance (ordinate) to cardiac output of plasma (abscissa). The correlation 
coefficient for the mean group results was r = 0.925 (n = 10). 
Both phenylephrine and L-NMMA also dose-dependently reduced the 
rate of noradrenaline release into plasma as they increased total peripheral 
resistance. The curvilinear relationship between noradrenaline release and 
vascular resistance produced by L-NMMA was virtually identical with that 
produced by phenylephrine. 
Dose-response curves for the % inhibition of basal noradrenaline release 
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Fig. 1. Dose-response curves for the % inhibition of noradrenaline release by 
phenylephrine (0) or L-NMMA (-) in the anaesthetized rabbit. Pretreatment base-
line values of noradrenaline release were determined prior to the administration 
of phenylephrine (2.5-20~gkg-1 min-I) or L-NMMA (3-100mgkg- I). Baseline 
noradrenaline release was 178 ± 17pmolkg-1min-1 (n = 21) in the phenylephrine 
group and 152 ± 16pmolkg-1 min-1 (n = 16) in the L-NMMA group. Shown are 
means ±SEM (for number of experiments, see text) and the dose-response curves 
drawn according to a fit of Hill's equation to the mean group results. The dose-
response parameters obtained for phenylephrine were Emax = 82.7 ± 5.3%, EDso = 
3.5 ± 0.4~gkg-1 and nH = 1.6 ± 0.3; the parameters for inhibition of noradrenaline 
release by L-NMMA were Emax = 69.1 ± 4.3%, ED so = 4.5 ± 0.8mgkg- 1 and 
nH = 0.9 ± 0.2 
by phenylephrine or L-NMMA are shown in Fig. 1. Phenylephrine showed 
a maximum inhibition of noradrenaline release of 82.7 ± 5.3%. The 
blockade of NO formation by L-NMMA produced a maximum inhibition of 
noradrenaline release of 69 ± 4.3%. 
L-arginine, given in three experiments subsequent to L-NMMA (see 
above), attenuated the inhibitory effect of L-NMMA on noradrenaline 
release by 63 % . 
Discussion 
The present results clearly confirm a physiological role for endothelium-
derived NO in the control of vascular tone in vivo. Inhibition of NO 
synthesis by L-NMMA was found to increase blood pressure and to decrease 
heart rate as has been also shown by others in anaesthetized guinea pigs 
(Aisaka et aI., 1989), rabbits (Rees et ai., 1989) and rats (Gardiner et ai., 
1990; Rees et aI., 1990). The observed L-NMMA-induced increases in 
blood pressure are due to a rise in total peripheral vascular resistance. This 
has been shown directly by measurements of regional vascular conductances 
in the rat (Gardiner et aI., 1990) and by determination of the total periph-
eral vascular resistance in the rabbit (present study). However, there may 
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be some species differences with respect to the maximum effects due to 
abolition of NO formation, since the attainable maximum increase in blood 
pressure in rats of about 46 mm Hg (Rees et al., 1990) was higher than that 
obtained in this study in rabbits (19mmHg). This difference even persists 
when the increases are expressed in % of baseline in order to take into 
account differences in pretreatment values. This is of particular significance, 
since the formation of NO has been reported to be dependent on the level 
of vascular tone (Vargas et al., 1990). Therefore, among other explana-
tions, differences between species in the basal rate of NO synthesis or in the 
baroreftex sensitivity may well be considered in the interpretation of 
haemodynamic responses to inhibition of endothelial NO synthesis. 
This study also provides evidence to show that inhibition of the L-
arginine:NO pathway not only reduces endothelium-dependent vasodilata-
tion, but also affects the neuronal vasoconstrictor component involved in 
the regulation of vascular tone. In our experiments the rate of noradrenaline 
release into plasma, but not the noradrenaline plasma concentration, was 
taken as a clearance-independent index of sympathetic tone, since L-NMMA 
as well as phenylephrine were found to cause cardiac output-dependent 
changes in noradrenaline plasma clearance. As shown in Fig. 1, L-NMMA 
dose-dependently inhibited noradrenaline release. This inhibition of release 
is likely to be mediated solely by the baroreftex, since the curvilinear rela-
tionship between noradrenaline release and vascular resistance produced by 
L-NMMA was nearly identical with that produced by phenylephrine. More-
over, the L-NMMA effects on both haemodynamics and noradrenaline 
release were attenuated to a similar extend by a 3-fold excess of L-arginine. 
From the obtained maximum inhibition of noradrenaline release by 
phenylephrine, it is concluded that the baroreftex-sensitive release com-
ponent amounts to 83% of the basal noradrenaline release. Inhibition of 
NO formation by L-NMMA maximallyreduced noradrenaline release by 
69%, suggesting that the counterregulation against the EDRF-induced 
peripheral vasodilatation accounts for 69% of noradrenaline release 
under-resting conditions. Hence, vasodilatation by the endogenous "nitro-
vasodilator" NO plays a significant role in the regulation of noradrenaline 
release. 
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